



Financial Snapshot

NASDAQ: CYTH | Share Price: \$6.72* | Market Cap: ~43M* | Shares Outstanding: ~6.4M *As of September 30, 2021

Investment Opportunity

Deep expertise with Cyclodextrins with over 10 years of patient exposure

- Lead program, Trappsol® Cyclo™ demonstrated to be safe and effective in multiple clinical studies in NPC
- Significant market opportunity in high value indications
- Leadership team with proven expertise
- Manufacturing at commercial scale inclusive of 60-month stability and 96hr In-use stability

Pipeline


Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Milestones
Trappsol® Cyclo™	Niemann-Pick Disease Type C					TransportNPC™ (Pivotal Phase 3 Study) Site activation ongoing and currently enrolling patients
Trappsol® Cyclo™	Alzheimer's Disease					FDA feedback from Type B meeting supports Phase 2 development strategy Expected Filing IND in H2 2021

Niemann-Pick Disease Type C (NPC)

Rare, fatal and progressive genetic disorder characterized by a defect in the NPC1 protein causing cholesterol and lipids to accumulate in cells of major organs leading to cell and tissue dysfunction.

Average Life Expectancy: (1) Before age 5 if symptoms appear in infancy, (2) Age 20 in juvenile onset, (3) Increasing diagnosis in later onset disease

NPC Prevalence



*Scope: United States + 79 other countries; *Commissioned Tessellon Inc - former Kantar Health experts with 25+ years of epidemiology and forecasting experience, (www.Tessellon.com); *Exhaustive literature search with a broad range of MESH terms.




NASDAQ: CYTH • cyclotherapeutics.com

Investor Relations | JTC Team | 833.475.8247 | cyth@jtcir.com

Trappsol® Cyclo™

A Potential Treatment for the Systemic and Neurological Symptoms of NPC



Alzheimer's Disease

Filing IND in H2 2021 for potential Phase 2 study

The Most Common Form of Dementia

An irreversible, progressive neurologic disorder that slowly degrades memory, thinking and social skills that affects a person's ability to function independently.

Similarities with NPC: (1) Cognitive decline, (2) Elevated levels of tau, (3) Amyloid plaques

- Affects more than 5 million people in the U.S.¹
- 6th leading cause of death in the U.S.¹
- 500,000 new cases every year²
- 13.8 million cases projected by 2050¹

1. <https://www.alz.org/alzheimers-dementia/facts-figures> | 2. <https://www.brightfocus.org/alzheimers/article/alzheimers-disease-facts-figures>

Target Upcoming Milestones with Potential to Drive Value

Niemann-Pick Disease Type C



Alzheimer's Disease

